Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 6,236 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 6,236 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $27.86, for a total transaction of $173,734.96. Following the transaction, the insider owned 304,270 shares of the company’s stock, valued at $8,476,962.20. This trade represents a 2.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total transaction of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Trading Down 0.3%

Shares of NYSE:HIMS traded down $0.08 during trading on Thursday, reaching $27.92. The company’s stock had a trading volume of 8,214,836 shares, compared to its average volume of 24,477,230. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $65.30. The firm’s 50 day simple moving average is $30.34 and its two-hundred day simple moving average is $27.51. The stock has a market capitalization of $6.51 billion, a PE ratio of -44.32 and a beta of 2.42.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the prior year, the business posted $0.17 EPS. The company’s revenue was up 38.2% on a year-over-year basis. On average, research analysts predict that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Hims & Hers and certain executives. The proposed class covers investors who purchased shares between August 4, 2025, and July 29, 2026, with November 2, 2026, set as the lead-plaintiff deadline. ClaimsFiler shareholder alert
• Negative Sentiment: The allegations center on potentially deceptive or unlawful privacy and billing practices, including issues connected with data sharing. These claims remain allegations, but could create legal liabilities and distract management. Hagens Berman class-action announcement
• Negative Sentiment: The legal-news flow reinforces concerns already reflected in recent selling pressure, while Hims & Hers continues to report losses and has substantial balance-sheet leverage. The stock has therefore remained volatile and below its recent 50-day average.
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, offering no new bullish catalyst or meaningful change to the current analyst view. Bank of America Hold rating

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Morgan Stanley raised their price target on Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research note on Friday, May 22nd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research note on Friday, August 7th. Finally, Truist Financial upped their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a report on Monday, August 24th. Three investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $32.43.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the business. Versant Capital Management Inc grew its position in Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after acquiring an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares during the last quarter. Compass Financial Management LLC bought a new stake in shares of Hims & Hers Health during the second quarter worth $50,000. Bogart Wealth LLC boosted its stake in shares of Hims & Hers Health by 180.7% during the first quarter. Bogart Wealth LLC now owns 2,526 shares of the company’s stock valued at $52,000 after purchasing an additional 1,626 shares during the period. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in shares of Hims & Hers Health during the fourth quarter valued at $59,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.